Cardiovascular disease in women has long been disregarded as being of minor importance, and hypertension likewise is often considered to be a low risk condition in women. In fact, only recently has scientific attention been drawn to the menopausal period, after which age-related blood pressure changes are greater in women than in man, hypertension becomes more prevalent in females, and global cardiovascular reaches a comparable level as in man. We must understand better the causes and mechanisms of these menopause-related changes before we can provide a coherent preventive and therapeutic strategy towards cardiovascular disease in postmenopausal women. The new interest in this question is displayed in the development of a new ACE-inhabitor, moexipril. A number of the efficacy and safety studies have been carried out exclusively in postmenopausal hypertensive patients with and without hormone replacement therapy, and we are finally beginning to optain valuable information on how to approch therapy in these patients.